Cervical cancer is one of the most prevalent malignant tumours worldwide in women between 15 and 44 years old, with about 500,000 new diagnoses per year. In Italy there are about 53,000 women diagnosed with cervical cancer, with a rate of 3,400 new cases/year. This cancer is caused by persistent infection with certain high-risk Human Papillomavirus (HPV) types. The Pap Test is a cytology-based test that is commonly used to diagnose the presence of tumour cells at the uterine cervix. Although the use of the Pap test has contributed to saving millions of lives and still does, its sensitivity and accuracy are very variable because this test mostly relies on the expertise of the operator. In addition to specialized operators, the Pap test requires specific equipment and laboratories, it is expensive, and it is considered invasive and annoying. On the other hand, HPV DNA tests are highly sensitive, but they are even more expensive and are poorly predictive, because only a few HPV infections will eventually lead to cancer development. A positive HPV DNA test usually forces the woman to undergo additional follow-up tests, such as the Pap test or more invasive analysis such colposcopy, in which a biopsy of the cervix is often taken. In this context, Ulisse BioMed business idea aims at developing innovative tests that are more reliable, easier to use, painless and also cheaper, thus alleviating the burden on the public health services. Moreover, considering their ease and immediacy of use, and especially given that these new tests can be performed outside the lab, it will be easy to expand their use into all social and economic contexts.